ArticleBMC biotechnology2026
B3GNT6 suppresses colorectal cancer progression by inhibiting the KRAS/ERK signaling pathway.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is one of the most common malignancies with high morbidity and mortality worldwide. B3GNT6 as been predicted to serve as a prognostic indicator for CRC patients, but its biological function and underlying mechanism in CRC remain largely unclear.
objectiveOur investigation was designed to clarify the biological function and molecular mechanism of B3GNT6 in CRC progression.
methodsThe mRNA and protein expression levels of B3GNT6 in CRC tissues and cell lines were examined using RT-qPCR and western blot assay. CCK-8, flow cytometry, and TUNEL staining were used to evaluate cell proliferation, cell cycle distribution, and apoptosis in vitro and in vivo. The migratory and invasive abilities of cells were determined by Transwell assay. Cell autophagy was analyzed by immunofluorescence staining. The expression of apoptosis-related proteins and key components in the KRAS/ERK signaling pathway was detected using RT-qPCR and western blot analysis.
resultsB3GNT6 was significantly downregulated in CRC tissues and cell lines. Functionally, B3GNT6 overexpression inhibited cell proliferation, autophagy, migration, and invasion, induced G2 phase cell cycle arrest and apoptosis, whereas these effects were abolished by KRAS overexpression. In vivo experiments further confirmed that B3GNT6 overexpression suppressed tumor growth and autophagy, and promoted apoptosis. Mechanistically, B3GNT6 overexpression inhibited the activation of the KRAS/ERK signaling pathway, while upregulation of KRAS had the opposite effect.
conclusionB3GNT6 inhibits colorectal cancer progression by blocking the KRAS/ERK signaling pathway. Thus, B3GNT6 may serve as a promising diagnostic and prognostic biomarker as well as a potential therapeutic target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.